Astellas Pharma Inc.
ALPMY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -2.08 | -1.82 | 8.53 |
| FCF Yield | 5.27% | 3.07% | 7.11% | 5.18% |
| EV / EBITDA | 13.09 | 18.03 | 13.18 | 14.09 |
| Quality | ||||
| ROIC | 2.62% | 0.63% | 11.70% | 6.82% |
| Gross Margin | 81.74% | 81.76% | 78.48% | 78.30% |
| Cash Conversion Ratio | 6.23 | 10.12 | 3.37 | 2.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.99% | 7.35% | 6.72% | -0.12% |
| Free Cash Flow Growth | 52.46% | -63.09% | 34.16% | -21.15% |
| Safety | ||||
| Net Debt / EBITDA | 2.59 | 3.00 | -0.72 | -0.43 |
| Interest Coverage | 2.32 | 2.13 | 32.51 | 31.46 |
| Efficiency | ||||
| Inventory Turnover | 1.17 | 1.18 | 1.87 | 1.84 |
| Cash Conversion Cycle | 235.10 | 201.06 | 141.00 | 136.68 |